메뉴 건너뛰기




Volumn 208, Issue 6, 2013, Pages 884-891

Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248

(13)  Andrade, Adriana a   Rosenkranz, Susan L b   Cillo, Anthony R c   Lu, Darlene b   Daar, Eric S d   Jacobson, Jeffrey M e   Lederman, Michael f   Acosta, Edward P g   Campbell, Thomas h   Feinberg, Judith i   Flexner, Charles a   Mellors, John W c   Kuritzkes, Daniel R j  


Author keywords

ACTG A5160s; ACTG A5166s; ACTG A5248; raltegravir; Roche ultrasensitive assay; single copy assay; viral decay

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; RALTEGRAVIR; VIRUS RNA;

EID: 84883206439     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit272     Document Type: Article
Times cited : (48)

References (21)
  • 2
    • 0028811974 scopus 로고
    • Viral dynamics in human immunodeficiency virus type 1 infection
    • Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-22.
    • (1995) Nature , vol.373 , pp. 117-122
    • Wei, X.1    Ghosh, S.K.2    Taylor, M.E.3
  • 3
    • 0030952479 scopus 로고    scopus 로고
    • Decay characteristics of HIV-1-infected compartments during combination therapy
    • Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-91.
    • (1997) Nature , vol.387 , pp. 188-191
    • Perelson, A.S.1    Essunger, P.2    Cao, Y.3
  • 4
    • 0033984045 scopus 로고    scopus 로고
    • The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
    • Ramratnam B, Mittler J, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000; 6:82-5.
    • (2000) Nat Med , vol.6 , pp. 82-85
    • Ramratnam, B.1    Mittler, J.2    Zhang, L.3
  • 5
    • 0032953920 scopus 로고    scopus 로고
    • Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
    • Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-25.
    • (1999) Nat Med , vol.5 , pp. 512-525
    • Finzi, D.1    Blankson, J.2    Siliciano, J.D.3
  • 6
    • 41649083599 scopus 로고    scopus 로고
    • Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
    • Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 105:3879-84.
    • (2008) Proc Natl Acad Sci USA , vol.105 , pp. 3879-3884
    • Palmer, S.1    Maldarelli, F.2    Wiegand, A.3
  • 7
    • 0038579210 scopus 로고    scopus 로고
    • Long term follow-up studies confirm the extraordinary stability of the latent reservoir for HIV-1 in resting CD4+ T cells
    • Siliciano JD, Kajdas J, Finzi D, et al. Long term follow-up studies confirm the extraordinary stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nature Med 2003; 9:727-8.
    • (2003) Nature Med , vol.9 , pp. 727-728
    • Siliciano, J.D.1    Kajdas, J.2    Finzi, D.3
  • 8
    • 0034723439 scopus 로고    scopus 로고
    • Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
    • Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646-50.
    • (2000) Science , vol.287 , pp. 646-650
    • Hazuda, D.J.1    Felock, P.2    Witmer, M.3
  • 9
    • 69449101785 scopus 로고    scopus 로고
    • Safety and efficacy of raltegravirbased versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial
    • Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravirbased versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796-806.
    • (2009) Lancet , vol.374 , pp. 796-806
    • Lennox, J.L.1    Dejesus, E.2    Lazzarin, A.3
  • 10
    • 37349120701 scopus 로고    scopus 로고
    • Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase
    • Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007; 21:2315-21.
    • (2007) AIDS , vol.21 , pp. 2315-2321
    • Murray, J.M.1    Emery, S.2    Kelleher, A.D.3
  • 11
    • 42449150053 scopus 로고    scopus 로고
    • Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle
    • Sedaghat AR, Dinoso JB, Shen L, et al. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci USA2008;105:4832-7.
    • (2008) Proc Natl Acad Sci USA , vol.105 , pp. 4832-4837
    • Sedaghat, A.R.1    Dinoso, J.B.2    Shen, L.3
  • 12
    • 0037199389 scopus 로고    scopus 로고
    • Modeling HIV viral rebound using non-linear mixed effects models
    • Fitzgerald AP, DeGruttola VG, Vaida F. Modeling HIV viral rebound using non-linear mixed effects models. Stat Med 2002; 21:2093-108.
    • (2002) Stat Med , vol.21 , pp. 2093-2108
    • Fitzgerald, A.P.1    Degruttola, V.G.2    Vaida, F.3
  • 13
    • 34047224560 scopus 로고    scopus 로고
    • Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s
    • Kuritzkes DR, Ribaudo HJ, Squires KE, et al. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis 2007; 195:1169-76.
    • (2007) J Infect Dis , vol.195 , pp. 1169-1176
    • Kuritzkes, D.R.1    Ribaudo, H.J.2    Squires, K.E.3
  • 14
    • 80855132700 scopus 로고    scopus 로고
    • Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection
    • Haubrich RH, Riddler SA, Ribaudo H, et al. Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection. AIDS 2001; 25:2269-78.
    • (2001) AIDS , vol.25 , pp. 2269-2278
    • Haubrich, R.H.1    Riddler, S.A.2    Ribaudo, H.3
  • 15
    • 77957900795 scopus 로고    scopus 로고
    • Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease
    • Jochmans D, Anders M, Keuleers I, et al. Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease. Retrovirology 2010; 7:89.
    • (2010) Retrovirology , vol.7 , pp. 89
    • Jochmans, D.1    Anders, M.2    Keuleers, I.3
  • 16
    • 77956856393 scopus 로고    scopus 로고
    • The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: A randomized controlled trial
    • pii
    • Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7:pii: e1000321.
    • (2010) PLoS Med , vol.7
    • Gandhi, R.T.1    Zheng, L.2    Bosch, R.J.3
  • 17
    • 67249121143 scopus 로고    scopus 로고
    • Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy
    • Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 2009; 106:9403-8.
    • (2009) Proc Natl Acad Sci USA , vol.106 , pp. 9403-9408
    • Dinoso, J.B.1    Kim, S.Y.2    Wiegand, A.M.3
  • 18
    • 79953000877 scopus 로고    scopus 로고
    • A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response
    • Dahl V, Sinclair E, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011; 203:960-8.
    • (2011) J Infect Dis , vol.203 , pp. 960-968
    • Dahl, V.1    Sinclair, E.2
  • 19
    • 33845366857 scopus 로고    scopus 로고
    • Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatmentnaive HIV-1-infected individuals
    • Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatmentnaive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43:509-15.
    • (2006) J Acquir Immune Defic Syndr , vol.43 , pp. 509-515
    • Markowitz, M.1    Morales-Ramirez, J.O.2    Nguyen, B.Y.3
  • 20
    • 34748860363 scopus 로고    scopus 로고
    • Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study
    • Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125-33.
    • (2007) J Acquir Immune Defic Syndr , vol.46 , pp. 125-133
    • Markowitz, M.1    Nguyen, B.Y.2    Gotuzzo, E.3
  • 21
    • 0029967721 scopus 로고    scopus 로고
    • HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time
    • Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-6.
    • (1996) Science , vol.271 , pp. 1582-1586
    • Perelson, A.S.1    Neumann, A.U.2    Markowitz, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.